Phaeno

What Phaeno does

Phaeno Inc. is an Irvine, California-based biotechnology company that has developed PSeq™ (Phased Sequencing Platform), a proprietary RNA sequencing technology designed to overcome the limitations of gene-level counting in conventional transcriptomics. The platform uses multifunctional tagging reagents (roughly 4.3 trillion unique tags) and intramolecular library construction to preserve the identity of individual RNA molecules through standard short-read NGS workflows, enabling full-length 5'-to-3' isoform-resolved quantification without dependence on prior transcript annotations and without statistical reconstruction. An automated data pipeline assembles reads into ML-native feature matrices that the company positions as inputs for downstream multi-omics and machine-learning workflows. Product capabilities claimed include greater than 87% rare isoform sensitivity (above 0.01% abundance), greater than 94% full-length isoform recovery, less than 2 hours of hands-on time per sample, and less than 24-hour turnaround from library to FASTA, with all data designated for research use only (RUO) and not validated for clinical diagnostics.

The company runs a sales-led, direct-engagement commercial model in which prospective customers — primarily academic and institutional researchers and pharmaceutical/biotech companies — request demos with project specifications (sample type, organism, study goals), submit RNA samples for processing, and receive results through a dedicated customer portal. Use cases span RNA isoform discovery, transcript quantification, multi-omics integration, ASO therapy development, biomarker validation, and cancer research. Marketing is conducted through an educational blog, email newsletter, and investor-focused content, with no publicly disclosed pricing, no named customer logos, no published patents, and no third-party benchmark validation in the source material. As of the inputs, Phaeno had raised $1.4M in total funding and operated with 1–10 employees while actively seeking additional qualified investors. The leadership team consists of four co-founders — William Agnew (PhD, CEO), Mark Emerick (PhD, CSO), Giovanni Parmigiani (PhD, CTO), and Hedi Mouchard (COO) — supplemented by a CFO/CBO, a small technical team of scientists and engineers, and a five-member advisory board.

Name

Phaeno

Legal name

Phaeno Inc.

Website

https://phaenobiotech.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1–10 employees

Short description

Phaeno is an Irvine-based biotechnology company offering PSeq™, a proprietary RNA sequencing platform that delivers isoform-resolved, ML-ready data using standard short-read NGS instruments. It serves academic researchers and pharmaceutical companies focused on transcriptomics, multi-omics, and precision medicine.

Ownership category

akta.pro rank

Product category

RNA Sequencing Services

NAICS

Software Publishers (513210), Scientific Research and Development Services (5417)

SIC

Laboratory Analytical Instruments (3826), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• RNA sequencing
• Isoform resolution
• Phased sequencing
• Multi-omics analysis
• Transcriptomics services

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. PSeq RNA Sequencing Services: Phaeno operates as a research and bioinformatics analysis platform providing RNA sequencing services using the PSeq technology. Revenue appears to come from processing customer RNA samples and delivering isoform-resolved sequencing data. The platform processes uploaded research data as non-clinical research data.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Phaeno operates the PSeq™ Phased Sequencing Platform, an RNA sequencing service that delivers full-length 5'-3' isoform-resolved, ML-ready outputs from standard short-read NGS instruments. The platform combines proprietary chemistry (4.3 trillion multifunctional tagging reagents) with an automated, annotation-independent software pipeline, enabling deterministic molecule-level RNA counting rather than statistical reconstruction.

Product overview

Phaeno offers a single unified product, the PSeq™ Phased Sequencing Platform, which combines proprietary chemistry, NGS-compatible sequencing, and an automated software pipeline. PSeq with Clear-Signal Architecture™ enables full-length, isoform-resolved RNA measurement by preserving source-molecule identity through short-read sequencing. The platform consists of: (1) PSeq Chemistry for molecular tagging and intramolecular library construction, (2) NGS-compatible sequencing workflow, and (3) an automated PSeq Software Stack for end-to-end data assembly. Key capabilities include isoform-resolved quantification, deterministic molecule-level counting, and ML-native feature matrix generation. The company also provides a customer portal for PSeq users and a technical brief resource. All offerings are research use only (RUO).

Differentiator

Problem solved

Functional benefit

Brands

• PSeq: Phaeno's Phased Sequencing Platform - a technology that produces fully quantitative, ML-ready outputs from short-read sequencing with isoform-resolved quantification. It provides molecule-level counting of every RNA, including rare and low-frequency isoforms.
• PSeq Clear-Signal Architecture

Products and services

• PSeq™ Phased Sequencing Platform A phased RNA sequencing service that produces fully quantitative, isoform-resolved, ML-ready outputs from short-read NGS instruments. The technology preserves molecule identity throughout sample processing, enabling full-length 5'-3' RNA sequencing including UTRs without dependence on prior annotations. Used by research institutions and pharmaceutical companies for biomarker discovery, therapeutic target identification, and multi-omics integration.

Quantifiable outcome

• >87% rare isoform sensitivity (>0.01% abundance) vs <5% for short-read RNA-Seq
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• QIAGEN: Sample-prep and bioinformatics provider serving molecular biology and clinical research customers. Comparable because it spans both the upstream sample-prep-to-data layer that PSeq sits in and the bioinformatics interpretation layer PHAeno also addresses.
• Oxford Nanopore Technologies: Long-read nanopore sequencing provider competing in the same isoform-resolved RNA sequencing space. PSeq's whole-molecule 5'–3' coverage on short-read hardware is positioned against ONT's direct RNA/cDNA nanopore offerings.
• Singular Genomics: Short-read NGS developer (G4 platform) building benchtop sequencers that target the same academic and translational research customers PHAeno sells into.
• Element Biosciences: Newer short-read sequencing platform (AVITI) that could host PSeq-style chemistries and competes in the same NGS-installed-base that PHAeno relies on for adoption friction.
• Illumina: Dominant short-read NGS platform provider whose sequencers and reagent kits form the substrate PSeq runs on. Highly comparable because PSeq's value proposition is explicitly differentiated against Illumina-style short-read RNA-Seq workflows in isoform recovery and rare-isoform sensitivity.
• Pacific Biosciences (PacBio): Long-read sequencing provider whose Iso-Seq workflow is PSeq's primary long-read benchmark for full-length isoform recovery. Highly relevant competitor in the isoform-resolved RNA sequencing category PHAeno is targeting.

Direct peers

• 10x Genomics: Provider of single-cell and spatial multi-omics platforms that compete in the same customer workflows of isoform-aware transcriptomics and multi-omics data layers that PHAeno targets with PSeq + multi-omics positioning.
• Lexogen: RNA-focused sequencing reagent and services provider (QuantSeq, TeloPrime) directly addressing RNA-seq and transcript quantification use cases that overlap with PSeq's target applications.
• TriLink BioTechnologies: Specialty nucleic acid chemistry manufacturer producing modified nucleotides, capping reagents, and tagging chemistries. Comparable as a potential competitor or partner in the proprietary tagging-reagent chemistry space that underpins PSeq's differentiation.

Others

• New England Biolabs: Major supplier of nucleic acid reagents and library prep enzymes used upstream of NGS. Comparable as an adjacent ecosystem participant whose workflows PSeq integrates with and whose reagents are critical to the sequencing ecosystem PHAeno participates in.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/phaeno-biotech

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phaeno